DOCSLIB.ORG

Mouse Shcbp1 Conditional Knockout Project (CRISPR/Cas9)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Mouse Shcbp1 Conditional Knockout Project (CRISPR/Cas9) https://www.alphaknockout.com Mouse Shcbp1 Conditional Knockout Project (CRISPR/Cas9) Objective: To create a Shcbp1 conditional knockout Mouse model (C57BL/6J) by CRISPR/Cas-mediated genome engineering. Strategy summary: The Shcbp1 gene (NCBI Reference Sequence: NM_011369 ; Ensembl: ENSMUSG00000022322 ) is located on Mouse chromosome 8. 13 exons are identified, with the ATG start codon in exon 1 and the TAG stop codon in exon 13 (Transcript: ENSMUST00000022945). Exon 4 will be selected as conditional knockout region (cKO region). Deletion of this region should result in the loss of function of the Mouse Shcbp1 gene. To engineer the targeting vector, homologous arms and cKO region will be generated by PCR using BAC clone RP24-78D8 as template. Cas9, gRNA and targeting vector will be co-injected into fertilized eggs for cKO Mouse production. The pups will be genotyped by PCR followed by sequencing analysis. Note: Mice homozygous for a knock-out allele exhibit normal viability, fertility and T cell development but show decreased susceptibility to experimental autoimmune encephalomyelitis. Exon 4 starts from about 19.36% of the coding region. The knockout of Exon 4 will result in frameshift of the gene. The size of intron 3 for 5'-loxP site insertion: 2817 bp, and the size of intron 4 for 3'-loxP site insertion: 10568 bp. The size of effective cKO region: ~709 bp. The cKO region does not have any other known gene. Page 1 of 8 https://www.alphaknockout.com Overview of the Targeting Strategy Wildtype allele gRNA region 5' gRNA region 3' 1 4 13 Targeting vector Targeted allele Constitutive KO allele (After Cre recombination) Legends Exon of mouse Shcbp1 Homology arm cKO region loxP site Page 2 of 8 https://www.alphaknockout.com Overview of the Dot Plot Window size: 10 bp Forward Reverse Complement Sequence 12 Note: The sequence of homologous arms and cKO region is aligned with itself to determine if there are tandem repeats. No significant tandem repeat is found in the dot plot matrix. So this region is suitable for PCR screening or sequencing analysis. Overview of the GC Content Distribution Window size: 300 bp Sequence 12 Summary: Full Length(7209bp) | A(28.62% 2063) | C(17.05% 1229) | T(35.05% 2527) | G(19.28% 1390) Note: The sequence of homologous arms and cKO region is analyzed to determine the GC content. No significant high GC-content region is found. So this region is suitable for PCR screening or sequencing analysis. Page 3 of 8 https://www.alphaknockout.com BLAT Search Results (up) QUERY SCORE START END QSIZE IDENTITY CHROM STRAND START END SPAN ----------------------------------------------------------------------------------------------- browser details YourSeq 3000 1 3000 3000 100.0% chr8 - 4765340 4768339 3000 browser details YourSeq 52 826 917 3000 93.4% chr16 - 8331956 8332475 520 browser details YourSeq 51 805 917 3000 79.1% chr15 - 36961886 36961989 104 browser details YourSeq 51 878 984 3000 88.1% chr1 + 157428036 157428147 112 browser details YourSeq 45 804 972 3000 72.6% chr14 + 123527491 123527621 131 browser details YourSeq 44 877 984 3000 70.4% chr4 - 145182864 145182971 108 browser details YourSeq 42 1568 1950 3000 69.6% chr1 + 93943371 93943690 320 browser details YourSeq 41 878 982 3000 69.6% chr19 - 14472432 14472536 105 browser details YourSeq 41 878 984 3000 69.2% chr13 - 100544167 100544273 107 browser details YourSeq 41 883 984 3000 93.8% chr10 - 84550041 84550145 105 browser details YourSeq 40 878 984 3000 62.7% chr14 - 48511038 48511128 91 browser details YourSeq 39 776 909 3000 62.7% chr1 - 74979699 74979788 90 browser details YourSeq 36 945 981 3000 100.0% chr9 + 59438448 59438492 45 browser details YourSeq 35 948 984 3000 97.3% chr17 + 12354135 12354171 37 browser details YourSeq 34 947 984 3000 94.8% chr15 - 3521211 3521248 38 browser details YourSeq 34 893 984 3000 68.5% chr7 + 44618242 44618333 92 browser details YourSeq 33 878 918 3000 92.4% chr14 - 79737565 79737606 42 browser details YourSeq 32 877 984 3000 64.9% chr18 - 19737759 19737866 108 browser details YourSeq 32 836 907 3000 86.2% chr16 - 22415160 22415229 70 browser details YourSeq 32 944 982 3000 94.5% chr6 + 39479275 39479321 47 Note: The 3000 bp section upstream of Exon 4 is BLAT searched against the genome. No significant similarity is found. BLAT Search Results (down) QUERY SCORE START END QSIZE IDENTITY CHROM STRAND START END SPAN ----------------------------------------------------------------------------------------------- browser details YourSeq 3000 1 3000 3000 100.0% chr8 - 4761631 4764630 3000 browser details YourSeq 395 2445 2990 3000 90.8% chr15 + 31978615 31979108 494 browser details YourSeq 395 2546 3000 3000 92.9% chr11 + 35645051 35645500 450 browser details YourSeq 392 2553 3000 3000 94.2% chr9 - 109037300 109037751 452 browser details YourSeq 392 2556 3000 3000 94.2% chr16 - 6546395 6546841 447 browser details YourSeq 390 2531 3000 3000 91.6% chr17 - 42119259 42119713 455 browser details YourSeq 388 2541 3000 3000 92.2% chr7 + 6462692 6463151 460 browser details YourSeq 387 2530 3000 3000 90.5% chr7 + 63387767 63388218 452 browser details YourSeq 387 2566 3000 3000 94.1% chr3 + 99489439 99489872 434 browser details YourSeq 387 2566 3000 3000 95.2% chr17 + 25238513 25239054 542 browser details YourSeq 386 2555 2996 3000 93.0% chr19 - 25293398 25293836 439 browser details YourSeq 386 2565 3000 3000 94.3% chr3 + 136161722 136162157 436 browser details YourSeq 385 2564 3000 3000 93.6% chr7 - 7024020 7024455 436 browser details YourSeq 385 2565 3000 3000 94.7% chr11 + 105114274 105114716 443 browser details YourSeq 384 2565 3000 3000 94.1% chr1 + 66464531 66464966 436 browser details YourSeq 383 2556 3000 3000 92.3% chr15 - 94809315 94809755 441 browser details YourSeq 383 2566 3000 3000 94.1% chr1 - 162769104 162769538 435 browser details YourSeq 382 2565 3000 3000 94.1% chr5 - 36724734 36725361 628 browser details YourSeq 382 2562 3000 3000 93.7% chr3 - 60047462 60047913 452 browser details YourSeq 382 2558 3000 3000 93.3% chr15 - 6677762 6678206 445 Note: The 3000 bp section downstream of Exon 4 is BLAT searched against the genome. No significant similarity is found. Page 4 of 8 https://www.alphaknockout.com Gene and protein information: Shcbp1 Shc SH2-domain binding protein 1 [ Mus musculus (house mouse) ] Gene ID: 20419, updated on 12-Aug-2019 Gene summary Official Symbol Shcbp1 provided by MGI Official Full Name Shc SH2-domain binding protein 1 provided by MGI Primary source MGI:MGI:1338802 See related Ensembl:ENSMUSG00000022322 Gene type protein coding RefSeq status VALIDATED Organism Mus musculus Lineage Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae; Murinae; Mus; Mus Also known as mPAL Expression Biased expression in CNS E11.5 (RPKM 16.0), liver E14 (RPKM 13.9) and 10 other tissues See more Orthologs human all Genomic context Location: 8; 8 A1.1 See Shcbp1 in Genome Data Viewer Exon count: 13 Annotation release Status Assembly Chr Location 108 current GRCm38.p6 (GCF_000001635.26) 8 NC_000074.6 (4735976..4779567, complement) Build 37.2 previous assembly MGSCv37 (GCF_000001635.18) 8 NC_000074.5 (4735980..4779534, complement) Chromosome 8 - NC_000074.6 Page 5 of 8 https://www.alphaknockout.com Transcript information: This gene has 7 transcripts Gene: Shcbp1 ENSMUSG00000022322 Description Shc SH2-domain binding protein 1 [Source:MGI Symbol;Acc:MGI:1338802] Gene Synonyms mPAL Location Chromosome 8: 4,735,976-4,779,567 reverse strand. GRCm38:CM001001.2 About this gene This gene has 7 transcripts (splice variants), 136 orthologues, 1 paralogue, is a member of 1 Ensembl protein family and is associated with 6 phenotypes. Transcripts Name Transcript ID bp Protein Translation ID Biotype CCDS UniProt Flags Shcbp1- ENSMUST00000022945.8 2156 668aa ENSMUSP00000022945.7 Protein coding CCDS22088 Q9Z179 TSL:1 201 GENCODE basic APPRIS P1 Shcbp1- ENSMUST00000207876.1 620 207aa ENSMUSP00000146454.1 Protein coding - A0A140LHK7 CDS 5' and 3' 205 incomplete TSL:3 Shcbp1- ENSMUST00000207262.1 508 170aa ENSMUSP00000146339.1 Protein coding - A0A140LHA7 CDS 5' and 3' 202 incomplete TSL:3 Shcbp1- ENSMUST00000207665.1 2606 No - Retained - - TSL:1 203 protein intron Shcbp1- ENSMUST00000208856.1 2365 No - Retained - - TSL:1 207 protein intron Shcbp1- ENSMUST00000208381.1 1937 No - Retained - - TSL:1 206 protein intron Shcbp1- ENSMUST00000207725.1 1022 No - Retained - - TSL:1 204 protein intron Page 6 of 8 https://www.alphaknockout.com 63.59 kb Forward strand 4.73Mb 4.74Mb 4.75Mb 4.76Mb 4.77Mb 4.78Mb Genes Gm6334-201 >processed pseudogene (Comprehensive set... Contigs AC155814.6 > AC129942.7 > Genes (Comprehensive set... < Shcbp1-201protein coding < Shcbp1-207retained intron < Shcbp1-203retained intron < Shcbp1-202protein coding < Shcbp1-205protein coding < Shcbp1-206retained intron < Shcbp1-204retained intron Regulatory Build 4.73Mb 4.74Mb 4.75Mb 4.76Mb 4.77Mb 4.78Mb Reverse strand 63.59 kb Regulation Legend CTCF Open Chromatin Promoter Promoter Flank Gene Legend Protein Coding Ensembl protein coding merged Ensembl/Havana Non-Protein Coding processed transcript pseudogene Page 7 of 8 https://www.alphaknockout.com Transcript: ENSMUST00000022945 < Shcbp1-201protein coding Reverse strand 43.58 kb ENSMUSP00000022... Low complexity (Seg) Superfamily Pectin lyase fold/virulence factor SMART Parallel beta-helix repeat Pfam Right handed beta helix domain PANTHER PTHR14695:SF8 PTHR14695 Gene3D Pectin lyase fold All sequence SNPs/i... Sequence variants (dbSNP and all other sources) Variant Legend missense variant synonymous variant Scale bar 0 60 120 180 240 300 360 420 480 540 600 668 We wish to acknowledge the following valuable scientific information resources: Ensembl, MGI, NCBI, UCSC. Page 8 of 8.
Load more

Recommended publications
  • PARSANA-DISSERTATION-2020.Pdf
    DECIPHERING TRANSCRIPTIONAL PATTERNS OF GENE REGULATION: A COMPUTATIONAL APPROACH by Princy Parsana A dissertation submitted to The Johns Hopkins University in conformity with the requirements for the degree of Doctor of Philosophy Baltimore, Maryland July, 2020 © 2020 Princy Parsana All rights reserved Abstract With rapid advancements in sequencing technology, we now have the ability to sequence the entire human genome, and to quantify expression of tens of thousands of genes from hundreds of individuals. This provides an extraordinary opportunity to learn phenotype relevant genomic patterns that can improve our understanding of molecular and cellular processes underlying a trait. The high dimensional nature of genomic data presents a range of computational and statistical challenges. This dissertation presents a compilation of projects that were driven by the motivation to efficiently capture gene regulatory patterns in the human transcriptome, while addressing statistical and computational challenges that accompany this data. We attempt to address two major difficulties in this domain: a) artifacts and noise in transcriptomic data, andb) limited statistical power. First, we present our work on investigating the effect of artifactual variation in gene expression data and its impact on trans-eQTL discovery. Here we performed an in-depth analysis of diverse pre-recorded covariates and latent confounders to understand their contribution to heterogeneity in gene expression measurements. Next, we discovered 673 trans-eQTLs across 16 human tissues using v6 data from the Genotype Tissue Expression (GTEx) project. Finally, we characterized two trait-associated trans-eQTLs; one in Skeletal Muscle and another in Thyroid. Second, we present a principal component based residualization method to correct gene expression measurements prior to reconstruction of co-expression networks.
    [Show full text]
  • Identify Key Genes and Pathways in Pancreatic Ductal Adenocarcinoma Via Bioinformatics Analysis
    Identify key genes and pathways in pancreatic ductal adenocarcinoma via bioinformatics analysis Huatian Luo Fujian Medical University https://orcid.org/0000-0002-6505-825X Da-qiu Chen Fujian Medical University Jing-jing Pan Fujian Medical University Zhang-wei Wu Fujian Medical University Can Yang Fujian Medical University Hao-jie Xu Fujian Medical University Shang-hua Xu Fujian Medical University Hong-da Cai Fujian Medical University Shi Chen ( [email protected] ) Fujian Provincial Hospital Yao-dong Wang ( [email protected] ) Fujian Medical University Research article Keywords: Bioinformatical analysis, Microarray, Pancreatic cancer, Differentially expressed gene Posted Date: April 7th, 2020 DOI: https://doi.org/10.21203/rs.3.rs-19826/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/14 Abstract Background: Pancreatic cancer has many pathologic types, among which pancreatic ductal adenocarcinoma (PDAC) is the most common one. Bioinformatics has become a very common tool for the selection of potentially pathogenic genes. Methods: Three data sets containing the gene expression proles of PDAC were downloaded from the gene expression omnibus (GEO) database. The limma package of R language was utilized to explore the differentially expressed genes (DEGs). To analyze functions and signaling pathways, the Database Visualization and Integrated Discovery (DAVID) was used. To visualize the protein-protein interaction (PPI) of the DEGs ,Cytoscape was performed under the utilization of Search Tool for the Retrieval of Interacting Genes (STRING). With the usage of the plug-in cytoHubba in cytoscape software, the hub genes were found out. To verify the expression levels of hub genes, Gene Expression Proling Interactive Analysis (GEPIA) was performed.
    [Show full text]
  • Reconstructing Cell Cycle Pseudo Time-Series Via Single-Cell Transcriptome Data—Supplement
    School of Natural Sciences and Mathematics Reconstructing Cell Cycle Pseudo Time-Series Via Single-Cell Transcriptome Data—Supplement UT Dallas Author(s): Michael Q. Zhang Rights: CC BY 4.0 (Attribution) ©2017 The Authors Citation: Liu, Zehua, Huazhe Lou, Kaikun Xie, Hao Wang, et al. 2017. "Reconstructing cell cycle pseudo time-series via single-cell transcriptome data." Nature Communications 8, doi:10.1038/s41467-017-00039-z This document is being made freely available by the Eugene McDermott Library of the University of Texas at Dallas with permission of the copyright owner. All rights are reserved under United States copyright law unless specified otherwise. File name: Supplementary Information Description: Supplementary figures, supplementary tables, supplementary notes, supplementary methods and supplementary references. CCNE1 CCNE1 CCNE1 CCNE1 36 40 32 34 32 35 30 32 28 30 30 28 28 26 24 25 Normalized Expression Normalized Expression Normalized Expression Normalized Expression 26 G1 S G2/M G1 S G2/M G1 S G2/M G1 S G2/M Cell Cycle Stage Cell Cycle Stage Cell Cycle Stage Cell Cycle Stage CCNE1 CCNE1 CCNE1 CCNE1 40 32 40 40 35 30 38 30 30 28 36 25 26 20 20 34 Normalized Expression Normalized Expression Normalized Expression 24 Normalized Expression G1 S G2/M G1 S G2/M G1 S G2/M G1 S G2/M Cell Cycle Stage Cell Cycle Stage Cell Cycle Stage Cell Cycle Stage Supplementary Figure 1 | High stochasticity of single-cell gene expression means, as demonstrated by relative expression levels of gene Ccne1 using the mESC-SMARTer data. For every panel, 20 sample cells were randomly selected for each of the three stages, followed by plotting the mean expression levels at each stage.
    [Show full text]
  • Temporal Proteomic Analysis of HIV Infection Reveals Remodelling of The
    1 1 Temporal proteomic analysis of HIV infection reveals 2 remodelling of the host phosphoproteome 3 by lentiviral Vif variants 4 5 Edward JD Greenwood 1,2,*, Nicholas J Matheson1,2,*, Kim Wals1, Dick JH van den Boomen1, 6 Robin Antrobus1, James C Williamson1, Paul J Lehner1,* 7 1. Cambridge Institute for Medical Research, Department of Medicine, University of 8 Cambridge, Cambridge, CB2 0XY, UK. 9 2. These authors contributed equally to this work. 10 *Correspondence: [email protected]; [email protected]; [email protected] 11 12 Abstract 13 Viruses manipulate host factors to enhance their replication and evade cellular restriction. 14 We used multiplex tandem mass tag (TMT)-based whole cell proteomics to perform a 15 comprehensive time course analysis of >6,500 viral and cellular proteins during HIV 16 infection. To enable specific functional predictions, we categorized cellular proteins regulated 17 by HIV according to their patterns of temporal expression. We focussed on proteins depleted 18 with similar kinetics to APOBEC3C, and found the viral accessory protein Vif to be 19 necessary and sufficient for CUL5-dependent proteasomal degradation of all members of the 20 B56 family of regulatory subunits of the key cellular phosphatase PP2A (PPP2R5A-E). 21 Quantitative phosphoproteomic analysis of HIV-infected cells confirmed Vif-dependent 22 hyperphosphorylation of >200 cellular proteins, particularly substrates of the aurora kinases. 23 The ability of Vif to target PPP2R5 subunits is found in primate and non-primate lentiviral 2 24 lineages, and remodeling of the cellular phosphoproteome is therefore a second ancient and 25 conserved Vif function.
    [Show full text]
  • MEIS2 Promotes Cell Migration and Invasion in Colorectal Cancer
    ONCOLOGY REPORTS 42: 213-223, 2019 MEIS2 promotes cell migration and invasion in colorectal cancer ZIANG WAN1*, RUI CHAI1*, HANG YUAN1*, BINGCHEN CHEN1, QUANJIN DONG1, BOAN ZHENG1, XIAOZHOU MOU2, WENSHENG PAN3, YIFENG TU4, QING YANG5, SHILIANG TU1 and XINYE HU1 1Department of Colorectal Surgery, 2Clinical Research Institute and 3Department of Gastroenterology, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang 310014; 4Department of Pathology, College of Basic Medical Sciences, Shenyang Medical College, Shenyang, Liaoning 110034; 5Department of Academy of Life Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, P.R. China Received October 9, 2018; Accepted March 18, 2019 DOI: 10.3892/or.2019.7161 Abstract. Colorectal cancer (CRC) is one of the most common 5-year survival rate of metastatic CRC is as low as ~10%. In types of malignancy worldwide. Distant metastasis is a key the past few decades, several regulators of CRC metastasis cause of CRC‑associated mortality. MEIS2 has been identified have been identified, including HNRNPLL and PGE2 (4,5). to be dysregulated in several types of human cancer. However, HNRNPLL has been revealed to modulate alternative splicing the mechanisms underlying the regulatory role of MEIS2 in of CD44 during the epithelial-mesenchymal transition (EMT), CRC metastasis remain largely unknown. For the first time, which leads to suppression of CRC metastasis (4). PGE2 the present study demonstrated that MEIS2 serves a role as a induced an expansion of CRC stem cells to promote liver promoter of metastasis in CRC. In vivo and in vitro experiments metastases in mice by activating NF-κB (5).
    [Show full text]
  • SHCBP1 Promotes Synovial Sarcoma Cell Metastasis Via Targeting TGF-Β1
    Peng et al. Journal of Experimental & Clinical Cancer Research (2017) 36:141 DOI 10.1186/s13046-017-0616-z RESEARCH Open Access SHCBP1 promotes synovial sarcoma cell metastasis via targeting TGF-β1/Smad signaling pathway and is associated with poor prognosis Changliang Peng1, Hui Zhao2, Yan Song3, Wei Chen4, Xiaoying Wang5, Xiaoli Liu6, Cheng Zhang1, Jie Zhao1,JiLi1, Guanghui Cheng7, Dongjin Wu1, Chunzheng Gao1 and Xiuwen Wang1* Abstract Background: Our previous studies reported that SHC SH2-domain binding protein 1 (SHCBP1) functions as an oncogene via promoting cell proliferations in synovial sarcoma (SS) cells. However, whether SHCBP1 has any effect on tumor metastasis remains unexplored. Methods: The expression of SHCBP1 was analyzed in 76 SS tissues and two SS cell lines by immunohistochemistry and real-time RT-PCR. The relationship between SHCBP1 expression and the clinicopathological features of SS was investigated. The role of SHCBP1 in SS cell adhesion, migration, invasion and angiogenesis was explored by adhesion, Wound healing, Transwell, and Matrigel tube formation assays. Western blotting was conducted to detect the protein expressions of TGF-β1/Smad signaling pathway and EMT-related markers. The key molecules associated with migration, invasion and EMT were evaluated by immunohistochemistry in tumor specimens. Results: In current study, we demonstrated that SHCBP1 overexpression significantly enhanced adhesion, migration, invasion and angiogenesis of SS cells. In contrast, SHCBP1 knockdown elicited the opposite effects on these phenotypes in vitro. SHCBP1 promoted tumor metastasis through inducing epithelial-mesenchymal transition (EMT) in SS cells. SHCBP1 knockdown could block the incidence of metastasis and EMT in SS cells. Furthermore, transforming growth factor-β1 (TGF-β1) induced SHCBP1 expression in a time-dependent pattern and SHCBP1 knockdown inhibited TGF-β1-induced EMT.
    [Show full text]
  • Number 3 March 2016 Atlas of Genetics and Cytogenetics in Oncology and Haematology
    Volume 1 - Number 1 May - September 1997 Volume 20 - Number 3 March 2016 Atlas of Genetics and Cytogenetics in Oncology and Haematology OPEN ACCESS JOURNAL INIST-CNRS Scope The Atlas of Genetics and Cytogenetics in Oncology and Haematologyis a peer reviewed on-line journal in open access, devoted to genes, cytogenetics, and clinical entities in cancer, and cancer-prone diseases. It is made for and by: clinicians and researchers in cytogenetics, molecular biology, oncology, haematology, and pathology. One main scope of the Atlas is to conjugate the scientific information provided by cytogenetics/molecular genetics to the clinical setting (diagnostics, prognostics and therapeutic design), another is to provide an encyclopedic knowledge in cancer genetics. The Atlas deals with cancer research and genomics. It is at the crossroads of research, virtual medical university (university and post-university e-learning), and telemedicine. It contributes to "meta-medicine", this mediation, using information technology, between the increasing amount of knowledge and the individual, having to use the information. Towards a personalized medicine of cancer. It presents structured review articles ("cards") on: 1- Genes, 2- Leukemias, 3- Solid tumors, 4- Cancer-prone diseases, and also 5- "Deep insights": more traditional review articles on the above subjects and on surrounding topics. It also present 6- Case reports in hematology and 7- Educational items in the various related topics for students in Medicine and in Sciences. The Atlas of Genetics and Cytogenetics in Oncology and Haematology does not publish research articles. See also: http://documents.irevues.inist.fr/bitstream/handle/2042/56067/Scope.pdf Editorial correspondance Jean-Loup Huret, MD, PhD, Genetics, Department of Medical Information, University Hospital F-86021 Poitiers, France phone +33 5 49 44 45 46 [email protected] or [email protected] .
    [Show full text]
  • Transdifferentiation of Human Mesenchymal Stem Cells
    Transdifferentiation of Human Mesenchymal Stem Cells Dissertation zur Erlangung des naturwissenschaftlichen Doktorgrades der Julius-Maximilians-Universität Würzburg vorgelegt von Tatjana Schilling aus San Miguel de Tucuman, Argentinien Würzburg, 2007 Eingereicht am: Mitglieder der Promotionskommission: Vorsitzender: Prof. Dr. Martin J. Müller Gutachter: PD Dr. Norbert Schütze Gutachter: Prof. Dr. Georg Krohne Tag des Promotionskolloquiums: Doktorurkunde ausgehändigt am: Hiermit erkläre ich ehrenwörtlich, dass ich die vorliegende Dissertation selbstständig angefertigt und keine anderen als die von mir angegebenen Hilfsmittel und Quellen verwendet habe. Des Weiteren erkläre ich, dass diese Arbeit weder in gleicher noch in ähnlicher Form in einem Prüfungsverfahren vorgelegen hat und ich noch keinen Promotionsversuch unternommen habe. Gerbrunn, 4. Mai 2007 Tatjana Schilling Table of contents i Table of contents 1 Summary ........................................................................................................................ 1 1.1 Summary.................................................................................................................... 1 1.2 Zusammenfassung..................................................................................................... 2 2 Introduction.................................................................................................................... 4 2.1 Osteoporosis and the fatty degeneration of the bone marrow..................................... 4 2.2 Adipose and bone
    [Show full text]
  • Somatic Mutations in Early Onset Luminal Breast Cancer
    www.oncotarget.com Oncotarget, 2018, Vol. 9, (No. 32), pp: 22460-22479 Research Paper Somatic mutations in early onset luminal breast cancer Giselly Encinas1,*, Veronica Y. Sabelnykova2,*, Eduardo Carneiro de Lyra3, Maria Lucia Hirata Katayama1, Simone Maistro1, Pedro Wilson Mompean de Vasconcellos Valle1, Gláucia Fernanda de Lima Pereira1, Lívia Munhoz Rodrigues1, Pedro Adolpho de Menezes Pacheco Serio1, Ana Carolina Ribeiro Chaves de Gouvêa1, Felipe Correa Geyer1, Ricardo Alves Basso3, Fátima Solange Pasini1, Maria del Pilar Esteves Diz1, Maria Mitzi Brentani1, João Carlos Guedes Sampaio Góes3, Roger Chammas1, Paul C. Boutros2,4,5 and Maria Aparecida Azevedo Koike Folgueira1 1Instituto do Cancer do Estado de Sao Paulo, Departamento de Radiologia e Oncologia, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil 2Ontario Institute for Cancer Research, Toronto, Canada 3Instituto Brasileiro de Controle do Câncer, São Paulo, Brazil 4Department of Medical Biophysics, University of Toronto, Toronto, Canada 5Department of Pharmacology and Toxicology, University of Toronto, Toronto, Canada *These authors have contributed equally to this work Correspondence to: Maria Aparecida Azevedo Koike Folgueira, email: [email protected] Keywords: breast cancer; young patients; somatic mutation; germline mutation; luminal subtype Received: September 26, 2017 Accepted: March 06, 2018 Published: April 27, 2018 Copyright: Encinas et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Breast cancer arising in very young patients may be biologically distinct; however, these tumors have been less well studied.
    [Show full text]
  • Identification of RAD54 Homolog B As a Promising Therapeutic Target for Breast Cancer
    5350 ONCOLOGY LETTERS 18: 5350-5362, 2019 Identification of RAD54 homolog B as a promising therapeutic target for breast cancer JING FENG1,2*, JUANJUAN HU1,2* and YING XIA1,2 1Institute of Chemical Component Analysis of Traditional Chinese Medicine, Chongqing Medical and Pharmaceutical College; 2Engineering Research Center of Pharmaceutical Sciences, Chongqing 401331, P.R. China Received January 24, 2019; Accepted July 26, 2019 DOI: 10.3892/ol.2019.10854 Abstract. Breast cancer is a recognized threat to the health Introduction of women globally. Due to the lack of the knowledge about the molecular pathogenesis of breast cancer, therapeutic Cancer is considered to be one of the most dangerous factors strategies remain inadequate, especially for aggressive breast to human life. The global cancer statistics for 2018 demon- cancer. In the present study, sequential bioinformatics analysis strated that breast cancer exhibits the highest morbidity and was performed using data from the GSE20711 dataset, and mortality rates in females worldwide compared with other the results demonstrated that three genes may impact the types of cancer (1). Several therapeutic strategies have been survival of patients with breast cancer. One of these genes, developed for breast cancer treatment, including surgery, RAD54 homolog B (RAD54B), may be a potential prognostic chemotherapy, radiotherapy, hormone therapy and newly factor for breast cancer. A signature was established that improved immunotherapy (2). However, due to the high could evaluate the overall survival for patients with breast heterogeneity among different types of breast cancer, the cancer based on the risk score calculated from RAD54B prognosis for a number of patients is still poor, especially for expression and the Tumor-Node-Metastasis (TNM) stage patients with distant metastases, who are usually diagnosed [risk score=expRAD54B x 0.236 + TNM stage (I/II=0 or at a late stage (3).
    [Show full text]
  • View See Ref
    Finelli et al. Molecular Cytogenetics 2012, 5:16 http://www.molecularcytogenetics.org/content/5/1/16 RESEARCH Open Access Juxtaposition of heterochromatic and euchromatic regions by chromosomal translocation mediates a heterochromatic long- range position effect associated with a severe neurological phenotype Palma Finelli1,2*, Silvia Maria Sirchia3,4, Maura Masciadri1, Milena Crippa1, Maria Paola Recalcati1, Daniela Rusconi1, Daniela Giardino1, Laura Monti3, Francesca Cogliati1, Francesca Faravelli5, Federica Natacci6, Leonardo Zoccante7, Bernardo Dalla Bernardina7, Silvia Russo1 and Lidia Larizza1,3 Abstract Background: The term “position effect” is used when the expression of a gene is deleteriously affected by an alteration in its chromosomal environment even though the integrity of the protein coding sequences is maintained. We describe a patient affected by epilepsy and severe neurodevelopment delay carrying a balanced translocation t(15;16)(p11.2;q12.1)dn that we assume caused a position effect as a result of the accidental juxtaposition of heterochromatin in the euchromatic region. Results: FISH mapped the translocation breakpoints (bkps) to 15p11.2 within satellite III and the 16q12.1 euchromatic band within the ITFG1 gene. The expression of the genes located on both sides of the translocation were tested by means of real-time PCR and three, all located on der(16), were found to be variously perturbed: the euchromatic gene NETO2/BTCL2 was silenced, whereas VPS35 and SHCBP1, located within the major heterochromatic block of chromosome 16q11.2, were over-expressed. Pyrosequencing and chromatin immunoprecipitation of NETO2/BTCL2 and VPS35 confirmed the expression findings. Interphase FISH analysis showed that der(16) localised to regions occupied by the beta satellite heterochromatic blocks more frequently than der(15).
    [Show full text]
  • Persister State-Directed Transitioning and Vulnerability in Melanoma
    bioRxiv preprint doi: https://doi.org/10.1101/2020.04.01.999847; this version posted March 1, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Persister state-directed transitioning and vulnerability in melanoma Heike Chauvistré1, Batool Shannan1, Sheena M. Daignault2, Robert J. Ju2, Daniel Picard3, Stefanie Egetemaier1, Renáta Váraljai1, Antonio Sechi4, Farnusch Kaschani5, 6, Oliver Keminer7, 8, Samantha J. Stehbens2, Qin Liu9, Xiangfan Yin9, Kirujan Jeyakumar10, Felix C. E. Vogel1, †, Clemens Krepler9, Vito W. Rebecca9, Linda Kubat11, 12, Smiths S Lueong12, 13, Jan Forster12, 14, Susanne Horn1, Marc Remke3, Michael Ehrmann6, 15, Annette Paschen1, Jürgen C. Becker1, 11, 12, Iris Helfrich1, Daniel Rauh10, Markus Kaiser5, 6, Sheraz Gul7, 8, Meenhard Herlyn9, José Neptuno Rodríguez-López16, Nikolas K. Haass2, Dirk Schadendorf1, 6 & Alexander Roesch1, 6 # 1 Department of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK). 2 The University of Queensland Diamantina Institute, The University of Queensland, Brisbane, Qld, Australia. 3 Department of Pediatric Oncology, hematology, and Clinical Immunology, Medical Faculty, University hospital Düsseldorf, Düsseldorf, Germany; Department of Neuropathology, Medical Faculty, University hospital Düsseldorf, Düsseldorf, Germany; Department of Pediatric Neuro- Oncogenomics, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Düsseldorf, Germany. 4 Institute for Biomedical Engineering, Department of Cell Biology, RWTH Aachen University Medical School, Aachen, Germany; Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, Aachen, Germany. 5 Chemical Biology, Faculty of Biology, University of Duisburg-Essen, Essen, Germany. 6 Center for Medical Biotechnology (ZMB), University of Duisburg-Essen, Essen, Germany.
    [Show full text]